Ryan D Maynard - Net Worth and Insider Trading
Ryan D Maynard Net Worth
The estimated net worth of Ryan D Maynard is at least $67,969 dollars as of 2024-06-06. Ryan D Maynard is the Director of Iovance Biotherapeutics Inc and owns about 7,500 shares of Iovance Biotherapeutics Inc (IOVA) stock worth over $62,400. Ryan D Maynard is the CHIEF FINANCIAL OFFICER of Cara Therapeutics Inc and owns about 8,012 shares of Cara Therapeutics Inc (CARA) stock worth over $5,569. Ryan D Maynard is also the EVP & CFO of Rigel Pharmaceuticals Inc and owns about 0 shares of Rigel Pharmaceuticals Inc (RIGL) stock worth over $0. Details can be seen in Ryan D Maynard's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ryan D Maynard has not made any transactions after 2023-02-08 and currently still holds the listed stock(s).
Transaction Summary of Ryan D Maynard
Ryan D Maynard Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ryan D Maynard owns 3 companies in total, including Iovance Biotherapeutics Inc (IOVA) , Rigel Pharmaceuticals Inc (RIGL) , and Cara Therapeutics Inc (CARA) .
Click here to see the complete history of Ryan D Maynard’s form 4 insider trades.
Insider Ownership Summary of Ryan D Maynard
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| IOVA | Iovance Biotherapeutics Inc | 2022-05-31 | director |
| RIGL | Rigel Pharmaceuticals Inc | 2017-11-03 | VP Finance & Acting CFO |
| CARA | Cara Therapeutics Inc | 2023-02-08 | Chief Financial Officer |
Ryan D Maynard Latest Holdings Summary
Ryan D Maynard currently owns a total of 3 stocks. Among these stocks, Ryan D Maynard owns 7,500 shares of Iovance Biotherapeutics Inc (IOVA) as of May 31, 2022, with a value of $62,400 and a weighting of 91.81%. Ryan D Maynard owns 8,012 shares of Cara Therapeutics Inc (CARA) as of February 8, 2023, with a value of $5,569 and a weighting of 8.19%. Ryan D Maynard also owns 0 shares of Rigel Pharmaceuticals Inc (RIGL) as of November 3, 2017, with a value of $0 and a weighting of 0%.
Latest Holdings of Ryan D Maynard
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| IOVA | Iovance Biotherapeutics Inc | 2022-05-31 | 7,500 | 8.32 | 62,400 |
| CARA | Cara Therapeutics Inc | 2023-02-08 | 8,012 | 0.70 | 5,569 |
| RIGL | Rigel Pharmaceuticals Inc | 2017-11-03 | 0 | 0.98 | 0 |
Holding Weightings of Ryan D Maynard
Ryan D Maynard Form 4 Trading Tracker
According to the SEC Form 4 filings, Ryan D Maynard has made a total of 1 transactions in Iovance Biotherapeutics Inc (IOVA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Iovance Biotherapeutics Inc is the acquisition of 7,500 shares on May 31, 2022, which cost Ryan D Maynard around $50,625.
According to the SEC Form 4 filings, Ryan D Maynard has made a total of 1 transactions in Cara Therapeutics Inc (CARA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Cara Therapeutics Inc is the sale of 5,488 shares on February 8, 2023, which brought Ryan D Maynard around $2,909.
According to the SEC Form 4 filings, Ryan D Maynard has made a total of 0 transactions in Rigel Pharmaceuticals Inc (RIGL) over the past 5 years. The most-recent trade in Rigel Pharmaceuticals Inc is the sale of 100,000 shares on November 3, 2017, which brought Ryan D Maynard around $390,000.
Insider Trading History of Ryan D Maynard
- 1
Ryan D Maynard Trading Performance
GuruFocus tracks the stock performance after each of Ryan D Maynard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ryan D Maynard is 58.81%. GuruFocus also compares Ryan D Maynard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ryan D Maynard within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ryan D Maynard's insider trading performs compared to the benchmark.
Performance of Ryan D Maynard
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 69.93 | | | | | |
| Relative Return to S&P 500(%) | 77.36 | | | | | |
Ryan D Maynard Ownership Network
Ryan D Maynard Owned Company Details
What does Iovance Biotherapeutics Inc do?
Who are the key executives at Iovance Biotherapeutics Inc?
Ryan D Maynard is the director of Iovance Biotherapeutics Inc. Other key executives at Iovance Biotherapeutics Inc include General Counsel Frederick G Vogt , Chief Operating Officer Igor Bilinsky , and Chief Financial Officer Jean-marc Bellemin .
Iovance Biotherapeutics Inc (IOVA) Insider Trades Summary
Over the past 18 months, Ryan D Maynard made no insider transaction in Iovance Biotherapeutics Inc (IOVA). Other recent insider transactions involving Iovance Biotherapeutics Inc (IOVA) include a net purchase of 270,000 shares made by Merrill A Mcpeak , and a net purchase of 10,000,000 shares made by Wayne P. Rothbaum .
In summary, during the past 3 months, insiders sold 0 shares of Iovance Biotherapeutics Inc (IOVA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iovance Biotherapeutics Inc (IOVA) were sold and 10,270,000 shares were bought by its insiders, resulting in a net purchase of 10,270,000 shares.
Iovance Biotherapeutics Inc (IOVA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Iovance Biotherapeutics Inc Insider Transactions
Ryan D Maynard Mailing Address
Above is the net worth, insider trading, and ownership report for Ryan D Maynard. You might contact Ryan D Maynard via mailing address: Rigel Pharmaceuticals, Inc., 1180 Veterans Blvd., South San Francisco Ca 94080.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
